The United Laboratories International Holdings Limited provided earnings guidance for the year ended December 31, 2014. The board of the directors of the company based on the unaudited consolidated management accounts of the company for the year ended 31 December 2014 prepared in accordance with Hong Kong Financial Reporting Standards, the group's unaudited annual results for the year ended 31 December 2014 is expected to report a substantial increase to a net profit of not less than HKD 620,000,000, while the net profit for the year ended 31 December 2013 is approximately HKD 48,000,000. The substantial increase in annual net profit of the Group for the year ended 31 December 2014 is attributable to a number of factors as: the overall gross profit of the group was improved due to decrease in production costs through production capacity being steadily released and the production technology of enzymatic bulk amoxicillin being mature of the Inner Mongolian's plant; in light of cessation of the operations of the Chengdu plant last year, a subsidy income from the local government of approximately HKD 390,000,000 was received during the year; the construction of the new facilities in Inner Mongolia plant gradually completed and commenced production this year.

The amount of interest capitalised was decreased in the year.